MabPlex International closes RMB500m Series B financing round

This round of financing was led by DT Capital and Golden China Fund, with participation from investment institutions including Sunshine Insurance Group, OrbiMed, China Merchants Securities Investment, Finnova Capital, Horus Capital, Unifortune, and Series A investors GF Venture Capital, Yantai Finance Investment Group and others.

Following the completion of the 400 million yuan Series A financing round in 2018, MabPlex International has successfully closed its Series B financing round recently, with a financing amount of more than 500 million yuan.

This round of financing was led by DT Capital and Golden China Fund, with participation from investment institutions including Sunshine InsuranceGroup, OrbiMed, China Merchants Securities Investment, Finnova Capital, Horus Capital, Unifortune, and Series A investors GF Venture Capital, Yantai Finance Investment Group and others.

MabPlex International is a leading and fully integrated, global Contract Development and Manufacturing Organization (CDMO) service provider, offers an advanced biologics platform and comprehensive and integrated solutions to global (bio-) pharmaceutical developers.

Founded in 2013, MabPlex currently has two sites in China (Yantai and Shanghai) and one site in the United States (San Diego, CA) offering high-quality services from biologics drug development to commercial manufacturing.

MabPlex currently has over 60,000 square meters of R&D and production facilities, a total of 9 monoclonal antibodies (mAb) Drug Substance (DS) production lines, 2 Antibody-drug Conjugate (ADC) DS production lines, as well as mAb formulation and ADC formulation lines.

To date, MabPlex International has participated in the research and development of nearly 100 novel drugs at home and abroad, helping clients obtain more than 20 clinical trial approvals in China, the United States, Australia and other countries. Four clients have used the clinical samples provided by MabPlex International to carry out phase I/II clinical trials in the United States.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/09/mabplex-international-closes-rmb500m-series-b-financing-round/.

Leave a Reply

Your email address will not be published. Required fields are marked *